🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

14 recruiting trials

for Locally Advanced or Metastatic HER2-Expressing Cancers

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357Phase 3272 sites📍 Scottsdale📍 Tucson📍 Tucson AstraZeneca · Tests: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) NCT07241793Phase 26 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: Adebrelimab, Trastuzumab Rezetecan Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites📍 Phoenix📍 Irvine📍 San Diego RayzeBio, Inc. · Tests: RYZ101, Standard of Care Endocrine Therapy Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Trastuzumab Rezetecan, Adebrelimab, Lenvatinib A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma NCT05302284Phase 32 sites📍 Beijing📍 Beijing RemeGen Co., Ltd. · Tests: RC48-ADC, Toripalimab, Gemcitabine, Cisplatin, Carboplatin SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors NCT07022002Phase 21 site📍 Hangzhou Shenyang Sunshine Pharmaceutical Co., LTD. · Tests: SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors NCT06031584Phase 1, Phase 21 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1 Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients NCT06650332Phase 1, Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: cadonilimab, Trastuzumab, XELOX, Disitamab Vedotin, mFOLFOX6 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer NCT06642545Phase 21 site📍 Beijing RemeGen Co., Ltd. · Tests: Disitamab Vedotin, RC148, Albumin-bound Paclitaxone, Toripalimab A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure NCT07606599Phase 32 sites📍 Hefei📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, Oxaliplatin, Calcium levofolinate, Fluorouracil, Irinotecan Hydrochloride Liposome SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors NCT07646626Phase 21 site📍 Hangzhou Shenyang Sunshine Pharmaceutical Co., LTD. · Tests: SSGJ-705, SSGJ-612, SSGJ-705 combined with chemotherapy DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy NCT06221748Phase 2, Phase 312 sites📍 Beijing📍 Xiamen📍 Harbin RemeGen Co., Ltd. · Tests: Disitamab Vedotin Injection, Cadonilimab Injection, Paclitaxel Injection Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors NCT06364410Phase 11 site📍 Houston National Cancer Institute (NCI) · Tests: Azenosertib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers NCT05356741Phase 1, Phase 212 sites📍 Duarte📍 Melbourne📍 Randwick Vir Biotechnology, Inc. · Tests: VIR-5818, pembrolizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy